Elizabeth Plimack, MD, MS | Authors


Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer

January 14, 2016

Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.

Pembrolizumab in Urothelial Cancer

June 26, 2015

Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.